Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Synbio Tech's Revenue for the
three
months ended in Jun. 2026 was NT$296 Mil. Synbio Tech's Total Assets for the quarter that ended in Jun. 2026 was NT$3,260 Mil. Therefore, Synbio Tech's Asset Turnover for the quarter that ended in Jun. 2026 was 0.09.
Asset Turnover is linked to ROE % through Du Pont Formula. Synbio Tech's annualizedROE % for the quarter that ended in Jun. 2026 was 17.08%. It is also linked to ROA % through Du Pont Formula. Synbio Tech's annualizedROA % for the quarter that ended in Jun. 2026 was 6.71%.
Note:
The Net Income data used here is four times the quarterly (Jun. 2026) net income data. The Revenue data used here is four times the quarterly (Jun. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.
It is also linked to ROA % through Du Pont Formula:
Synbio Tech's annulizedROA % for the quarter that ended in Jun. 2026 is
Note:
The Net Income data used here is four times the quarterly (Jun. 2026) net income data. The Revenue data used here is four times the quarterly (Jun. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.
Synbio Tech Asset Turnover Related Terms
Synbio Tech Asset Turnover Historical Data
* Premium members only.
The historical data trend for Synbio Tech's Asset Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:1295 vs VRTX, REGN, MRNA: Asset Turnover Comparison
For the Biotechnology subindustry, Synbio Tech's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synbio Tech Asset Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Synbio Tech's Asset Turnover distribution charts can be found below:
* The bar in red indicates where Synbio Tech's Asset Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.
Synbio Tech (ROCO:1295) has a Asset Turnover of 0.09 as of Jun. 2026. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Synbio Tech and its competitors.
Is Synbio Tech's Asset Turnover too high?
Synbio Tech's current Asset Turnover is 0.09. Overall, Synbio Tech has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Synbio Tech's Asset Turnover compare to VRTX and REGN?
Synbio Tech's Asset Turnover of 0.09 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for a Biotechnology company?
A good Asset Turnover depends on the Biotechnology industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Synbio Tech and its competitors. Synbio Tech's current Asset Turnover is 0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synbio Tech stock overvalued right now?
Based on GuruFocus' analysis, Synbio Tech (ROCO:1295) is currently considered Possible Value Trap. The stock's GF Value™ is NT$82.69, compared to a current price of NT$45.65 — trading 44.8% below its estimated fair value. The current Asset Turnover is 0.09. Synbio Tech's overall GF Score™ is 61/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For Synbio Tech (ROCO:1295), the current Asset Turnover is 0.09 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Synbio Tech (ROCO:1295) Overvalued in 2026?
Based on GuruFocus' analysis, Synbio Tech stock appears to be undervalued.
The current stock price of NT$45.65 is trading 44.8% below its estimated GF Value™ of NT$82.69.
GuruFocus considers Synbio Tech to be Possible Value Trap.
Key valuation signals for ROCO:1295:
Asset Turnover: 0.09
GF Value™: NT$82.69 vs. price of NT$45.65 (44.8% below fair value)
No single metric tells the full story. See the ROCO:1295 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Synbio Tech Inc focus on functional research and manufacturing of probiotics for human health and economic animals. It has two reportable segments, Taiwan and Mainland China Segment to engage in the production and R&D technologies of the Taiwan Segment, including the production and sales of concentrated fermentation liquid, lactobacillus plantarum solid drinks, and lactobacillus plantarum granules for animal husbandry. It generates majority of revenue from Taiwan segment includes production and sale of lactobacillus plantarum powder, lactobacillus plantarum fermentation derivative products, probiotics dietary supplements, probiotics products for pets and economic animals, and probiotics products. It has presence in Taiwan, China, Southeast Asia, and Others.
61GF Score
Get the complete analysis for ROCO:1295
Asset Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:1295 has been successfully added to your 
